Pacer Advisors Inc. Has $61.47 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Pacer Advisors Inc. cut its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 34.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,262,837 shares of the company’s stock after selling 1,699,384 shares during the quarter. Pacer Advisors Inc. owned 0.07% of Pacira BioSciences worth $61,472,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mercer Global Advisors Inc. ADV raised its stake in Pacira BioSciences by 39.0% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 12,686 shares of the company’s stock worth $363,000 after buying an additional 3,562 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Pacira BioSciences by 74.6% in the 2nd quarter. Hsbc Holdings PLC now owns 28,733 shares of the company’s stock worth $812,000 after purchasing an additional 12,275 shares in the last quarter. Squarepoint Ops LLC grew its position in Pacira BioSciences by 31.3% in the 2nd quarter. Squarepoint Ops LLC now owns 28,508 shares of the company’s stock valued at $816,000 after purchasing an additional 6,794 shares during the period. AQR Capital Management LLC grew its position in Pacira BioSciences by 9.6% in the 2nd quarter. AQR Capital Management LLC now owns 67,613 shares of the company’s stock valued at $1,934,000 after purchasing an additional 5,918 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Pacira BioSciences by 6.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company’s stock valued at $685,000 after purchasing an additional 1,354 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $25.66 on Tuesday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $34.01. The stock has a market capitalization of $1.18 billion, a P/E ratio of -12.64 and a beta of 0.76. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm’s 50 day moving average is $19.34 and its 200 day moving average is $17.52.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC lifted their price target on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays decreased their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, Pacira BioSciences has an average rating of “Hold” and a consensus price target of $24.50.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.